60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP · IEX Real-Time Price · USD
0.271
+0.025 (10.16%)
At close: Jul 19, 2024, 4:00 PM
0.240
-0.031 (-11.55%)
Pre-market: Jul 22, 2024, 7:39 AM EDT
SXTP Revenue
60 Degrees Pharmaceuticals had revenue of $569.86K in the twelve months ending March 31, 2024, with 20.57% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $80.66K. In the year 2023, 60 Degrees Pharmaceuticals had annual revenue of $253.57K.
Revenue (ttm)
$569.86K
Revenue Growth
+20.57%
P/S Ratio
5.80
Revenue / Employee
$189,954
Employees
3
Market Cap
3.31M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 253.57K | -257.64K | -50.40% |
Dec 31, 2022 | 511.21K | -4.99M | -90.71% |
Dec 31, 2021 | 5.50M | 3.66M | 197.98% |
Dec 31, 2020 | 1.85M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSXTP News
- 2 days ago - 60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study - GlobeNewsWire
- 13 days ago - 60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment - GlobeNewsWire
- 25 days ago - First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind - GlobeNewsWire
- 7 weeks ago - Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals Announces First Quarter 2024 Results - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required - GlobeNewsWire